These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

686 related items for PubMed ID: 11155820

  • 1. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO, Soori G, Wiemann MC, Schulof R, Dobbs TW, Ruben RH, DePriest CB, Church C.
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [Abstract] [Full Text] [Related]

  • 2. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH, Atzpodien J, Poliwoda H.
    Med Klin (Munich); 1996 Apr 12; 91 Suppl 3():44-9. PubMed ID: 8692119
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A.
    Cancer J Sci Am; 1997 Dec 12; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [Abstract] [Full Text] [Related]

  • 6. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeycutt PJ, Soori G.
    Cancer; 1998 May 01; 82(9):1677-81. PubMed ID: 9576288
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM.
    J Clin Oncol; 2005 Sep 20; 23(27):6747-55. PubMed ID: 16170182
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.
    Clin Cancer Res; 2000 Jun 20; 6(6):2201-8. PubMed ID: 10873069
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential chemoimmunotherapy for metastatic melanoma.
    Richards JM.
    Semin Oncol; 1991 Oct 20; 18(5 Suppl 7):91-5. PubMed ID: 1948135
    [Abstract] [Full Text] [Related]

  • 14. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
    Su PJ, Chen JS, Liaw CC, Chang HK, Wang HM, Yang TS, Lin YC, Liau CT, Yang HY, Yeh KY, Ho MM, Chang NJ, Wang CH, Chang JW.
    Chang Gung Med J; 2011 Oct 20; 34(5):478-86. PubMed ID: 22035892
    [Abstract] [Full Text] [Related]

  • 15. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR, Constenla DO, Moore J, Atkinson H, A'Hern RP, Dadian G, Riches PG, Gore ME.
    Br J Cancer; 1998 Apr 20; 77(8):1280-6. PubMed ID: 9579834
    [Abstract] [Full Text] [Related]

  • 16. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
    Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS.
    J Clin Oncol; 2007 Sep 01; 25(25):3802-7. PubMed ID: 17761969
    [Abstract] [Full Text] [Related]

  • 17. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.
    Richards JM, Gale D, Mehta N, Lestingi T.
    J Clin Oncol; 1999 Feb 01; 17(2):651-7. PubMed ID: 10080611
    [Abstract] [Full Text] [Related]

  • 18. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma.
    Thompson JA, Gold PJ, Fefer A.
    Semin Oncol; 1997 Feb 01; 24(1 Suppl 4):S44-8. PubMed ID: 9122734
    [Abstract] [Full Text] [Related]

  • 19. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Tan EH, Ang PT.
    Singapore Med J; 1996 Apr 01; 37(2):165-7. PubMed ID: 8942255
    [Abstract] [Full Text] [Related]

  • 20. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
    Sertoli MR, Queirolo P, Bajetta E, Del Vecchio M, Comella G, Barduagni L, Bernengo MG, Vecchio S, Criscuolo D, Bufalino R, Morabito A, Cascinelli N.
    Melanoma Res; 1999 Oct 01; 9(5):503-9. PubMed ID: 10596917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.